U.S. Vitrification Market Size, Share & Growth Analysis Report 2033
The U.S. vitrification market size was valued at USD 2.10 billion in 2023 and is projected to surpass around USD 9.34 billion by 2033, registering a CAGR of 16.09% over the forecast period of 2024 to 2033.
driven by factors such as changing sociodemographic aspects, increased infertility cases, and advanced fertility preservation techniques like IVF. Oocyte vitrification’s success, societal acceptance, and rising demand for cryopreservation services contribute to market expansion. Moreover, cancer patients and those at higher risk of cancer are encouraged to seek fertility preservation treatments, further fueling market growth.
The U.S. vitrification market accounted for over 20% of the global vitrification market in 2023. This can be attributed to several factors, including changing sociodemographic aspects and advancements in fertility preservation techniques. Approximately 10% women in the U.S., aged between 15 and 44 years, face challenges in conceiving as reported by the CDC. This increasing number of infertile individuals fuels the demand for fertility preservation services. With the help of advanced technologies, such as IVF, the chances of conceiving a child can be increased. In line with these trends, the CDC’s January 2023 report highlights that the average age of U.S. women having their first child has increased over time, further emphasizing the need for fertility preservation techniques.
Modern egg preservation methods, such as oocyte vitrification, have demonstrated significant success rates, increased social acceptance and driving market growth. Fertility preservation techniques have gained more acceptance in numerous countries, including legal endorsements of same-sex marriage and an increase in single parenthood. This has led to a higher demand for cryopreservation of eggs and sperm, resulting in increased demand for vitrification services. The American Cancer Society recommends egg freezing or embryo freezing for women with cancer to preserve fertility, further increasing the demand for fertility preservation services.
The growing acceptance of fertility preservation in society is also evident in the suggestion provided to individuals with a higher probability of acquiring cancer. These individuals are encouraged to seek egg preservation treatment for future use, as cancer treatments may affect fertility. With over 11,000 cervical cancer cases reported annually in the U.S., the need for fertility preservation techniques is on the rise. These factors collectively contribute to market expansion.
| Report Attribute | Details |
| Market Size in 2024 | USD 2.44 Billion |
| Market Size by 2033 | USD 9.34 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 16.09% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Specimen, end-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled |
Cook Medical LLC; Vitrolife; Genea Biomedx; NidaCon International AB; Minitube; IMV Technologies Group (Cryo Bio System); The Cooper Companies, Inc. (A CooperSurgical Fertility Company); FUJIFILM Corporation (FUJIFILM Irvine Scientific); Biotech, Inc.; Kitazato Corporation; Shenzhen VitaVitro Biotech
|
Oocytes led the segment in 2023 with over 40.19% of the total revenue share, driven by their effectiveness, as demonstrated by higher oocyte survival rates, pregnancy success, and live births. Advancements in oocyte vitrification techniques are expected to fuel market growth. The Society of Assisted Reproductive Technology (SART) observed a significant increase in egg-freezing processes in 2021 compared to 2019. The COVID-19 pandemic also led to a rise in egg-freezing adoption. Seattle Reproductive Medicine reported a 20% increase in 2020. Academic and research institutions are actively studying oocyte vitrification outcomes, while international organizations like WHO are supporting them through funding and grants.
The sperm segment is anticipated to register the fastest CAGR over the forecast period. This growth can be attributed to the increasing adoption of sperm vitrification, a technique with high potential for preserving sperm quality. Technological advancements have led to improved sperm survival rates after thawing. In addition, innovations in 3D printing may contribute to new methods of manufacturing freezing devices. For example, a recent report by the SART revealed a 25% increase in sperm-freezing procedures in 2022 compared to the previous year.
In 2023, IVF Clinics led the market by occupying nearly 60% of the total revenue generated. This advanced technique has significantly improved IVF success rates and the number of freezing cycles for oocytes and embryos. As more individuals opt for vitrification to preserve their biospecimens, the number of clinics offering this service is increasing.
A study published in Science Direct in February 2020 revealed that vitrified embryos exhibit better survival rates than those from the slow freezing process. The enhanced pregnancy and survival rates offered by vitrification have increased their use in IVF clinics. Market players are expanding their presence through strategies like acquisitions, partnerships, and facility expansions.
Biobanks are anticipated to grow at the fastest rate from 2024 to 2033 owing to the rising utility for biospecimen preservation and banking & processing. Cryobanking, complementing the vitrification market, has also seen significant growth due to a shift from slow freezing to the vitrification technique for preserving eggs, embryos, and sperm.
The rising number of ART procedures has fueled the demand for cryobanking services. Vitrification has revolutionized egg preservation by offering a rapid, cost-effective, and efficient mode of specimen preservation, leading to increased egg storage in biobanks. Furthermore, the emergence of online egg donor platforms is expected to stimulate the segment growth. For example, Tulip, an online egg donor matching platform launched in November 2020, managed to attract approximately 20,000 egg donors from 90% of U.S. agencies.
Key U.S. Vitrification Company Insights
The U.S. vitrification market exhibits a consolidated landscape, with a few prominent companies holding a substantial market share. This concentration may result in heightened competition among major players, while potentially restricting new entrants from accessing the market. Some key companies in the U.S. vitrification market are Cook Medical LLC; Vitrolife; Genea Biomedx; NidaCon International AB; Minitube; and IMV Technologies Group (Cryo Bio System), among others.
Notable companies in the industry are implementing diverse strategic approaches, including product launches, collaborations, and partnerships, to maintain and strengthen their market presence. Furthermore, they are focusing on innovation to drive advancements and introduce novel solutions for the market’s benefit.
For instance, in February 2024, Kitazato Corporation and IVF2.0 formed a strategic collaboration to revolutionize the IVF market with AI solutions. The partnership aimed to enhance real-time sperm selection based on ploidy prediction for ICSI and embryo ranking. Kitazato leveraged its global distribution network to introduce IVF2.0’s software, which assists embryologists in making critical decisions for improved fertility outcomes.
U.S. Vitrification Market Top Key Companies:
U.S. Vitrification Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Vitrification market.
By Specimen
By End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Specimen
1.2.2. End-use
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Specimen Outlook
2.2.2. End-use Outlook
2.3. Competitive Insights
Chapter 3. U.S. Vitrification Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.2.3. Market opportunity analysis
3.3. U.S. Vitrification Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Vitrification Market: Specimen Estimates & Trend Analysis
4.1. U.S. Vitrification Market: Specimen Dashboard
4.2. U.S. Vitrification Market: Specimen Movement Analysis
4.3. U.S. Vitrification Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.4. Oocytes
4.4.1. Market estimates and forecasts 2021 to 2033
4.4.2. Devices
4.4.2.1. Market estimates and forecasts 2021 to 2033
4.4.3. Kits & Consumables
4.4.3.1. Market estimates and forecasts 2021 to 2033
4.5. Embryo
4.5.1. Market estimates and forecasts 2021 to 2033
4.5.2. Devices
4.5.2.1. Market estimates and forecasts 2021 to 2033
4.5.3. Kits & Consumables
4.5.3.1. Market estimates and forecasts 2021 to 2033
4.6. Sperm
4.6.1. Market estimates and forecasts 2021 to 2033
Chapter 5. U.S. Vitrification Market: End-use Estimates & Trend Analysis
5.1. U.S. Vitrification Market: End-use Dashboard
5.2. U.S. Vitrification Market: End-use Movement Analysis
5.3. U.S. Vitrification Market Size & Forecasts and Trend Analyses, 2021 to 2033
5.4. IVF Clinics
5.4.1. Market estimates and forecasts 2021 to 2033
5.5. Biobanks
5.5.1. Market estimates and forecasts 2021 to 2033
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2023
6.3.4. Cook Medical LLC
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Vitrolife
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Genea Biomedx
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. NidaCon International AB
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Minitube
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. IMV Technologies Group (Cryo Bio System)
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. The Cooper Companies, Inc. (A CooperSurgical Fertility Company)
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. FUJIFILM Corporation (FUJIFILM Irvine Scientific)
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Biotech, Inc.
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
6.3.13. Kitazato Corporation
6.3.13.1. Company overview
6.3.13.2. Financial performance
6.3.13.3. Product benchmarking
6.3.13.4. Strategic initiatives
6.3.14. Shenzhen VitaVitro Biotech
6.3.14.1. Company overview
6.3.14.2. Financial performance
6.3.14.3. Product benchmarking
6.3.14.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers